FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

ASX CODE LAST PRICE % MOVE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET UPSIDE/DOWNSIDE
1AD $0.01 0.00% $0.01 $0.00

ACR $0.01 0.00% $0.02 $0.01

ACW $0.04 0.00% $0.07 $0.02

ADO $0.02 0.00% $0.05 $0.01

AFP $3.29

3.13%

$3.37 $2.20

AGN $0.16

6.67%

$0.77 $0.09

ARX $0.56 0.00% $0.80 $0.50 37.4

$0.94

67.9%

ATH $0.56

1.82%

$0.79 $0.01

AVH $1.43

-2.05%

$1.98 $1.00

$1.275

-10.8%

BIO $0.26 0.00% $0.62 $0.20 23.6

$0.75

188.5%

BOT $0.02 0.00% $0.18 $0.02

COV $0.36

2.86%

$0.90 $0.34

CSL $117.94

-2.83%

$275.79 $90.00 12.7

$130.584

10.7%

CUV $9.88

-1.69%

$14.00 $8.35 14.0

$15.00

51.8%

DXB $0.25

8.70%

$0.67 $0.16

GSS $0.06 0.00% $0.43 $0.06

$0.10

66.7%

IDT $0.03

-25.00%

$0.10 $0.03

ILA $0.42 0.00% $0.63 $0.14

IMM $0.05 0.00% $0.47 $0.03

$0.07

40.0%

IMU $0.09 0.00% $0.46 $0.09

$0.25

177.8%

IVX $0.04 0.00% $0.20 $0.03

LGP $0.08 0.00% $0.15 $0.06

MAP $0.05 0.00% $0.11 $0.04

$0.085

70.0%

MSB $2.34

0.86%

$3.31 $1.88 -30.5

$4.45

90.2%

MVP $0.38

-2.56%

$0.77 $0.37

$0.85

123.7%

MYX $2.77

0.73%

$6.50 $2.04

NEU $17.29

3.16%

$22.99 $11.00 44.2

$24.367

40.9%

NUZ $0.06 0.00% $0.19 $0.06

$0.20

233.3%

OCC $0.72

1.41%

$1.60 $0.70

$1.19

65.3%

OPT $0.01 0.00% $0.60 $0.01

OSL $1.15

-8.73%

$2.09 $0.37

PAR $0.18

5.88%

$0.47 $0.14

$0.45

150.0%

PER $0.01 0.00% $0.01 $0.00

PNV $0.95 0.00% $1.67 $0.87 98.3

$1.703

79.3%

PYC $1.61

-1.23%

$1.76 $0.85

$2.30

42.9%

RAC $2.05

0.49%

$4.90 $1.14

RCE $0.35

-5.41%

$0.73 $0.35

SNT $0.02 0.00% $0.07 $0.02

$0.06

200.0%

SPL $0.70 0.00% $0.79 $0.09

TLX $14.86

-2.94%

$21.96 $8.26 255.0

$26.225

76.5%

TRP $0.10

-16.67%

$0.48 $0.10

VIT $0.03 0.00% $0.08 $0.02

ZNO $0.06 0.00% $0.18 $0.03

Previous Stories
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023

Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics


Dr Boreham’s Crucible: PolyNovo

Jul 06 2023

Skin repair specialist PolyNovo remains confident in its firm growth path ahead


CSL Disappoints But Brokers Retain The Faith

Jun 15 2023

CSL’s trading and guidance fell -12% short of consensus forecasts but most brokers hold the faith


Dr Boreham’s Crucible: Dimerix

Jun 07 2023

A positive trial result could put a rocket on shares in Dimerix, reports Tim Boreham, but investors won’t know the answer until early 2024


Dr Boreham’s Crucible: Chimeric Therapeutics

May 26 2023

Tim Boreham reports cancer treatment biotech Chimeric has struggled, but may yet have a sting in its tail


Avita Medical Preps For Enlarged US Opportunity

May 17 2023

Brokers review first quarter results and pending regulatory approvals for Avita Medical


Dr Boreham’s Crucible: Radiopharm Theronostics

Apr 13 2023

Cancer detection biotech Radiopharm Theronostics is planning to list on the Nasdaq, and not without good reason, Tim Boreham explains


Dr Boreham’s Crucible: Avita Medical

Mar 29 2023

Tim Boreham highlights the global addressable market opportunity for Avita Medical’s skin graft technology, made famous by the Bali bombings